Recent News

Dr. John Cush Tweet
@RheumNow
Pre-RA: Antibodies Sort the Risk, Ultrasound Erosions Flag Severity Three ACR 2026 abstracts from the Leeds CCP cohort tested how to triage anti-CCP positive individuals with musculoskeletal symptoms. Serology and a few clinical items carried the prediction, while ultrasound https://t.co/91HG7xPS3o
Dr. John Cush Tweet
@RheumNow
Efgartigimod: A New Mechanism for Myositis? Abstracts come and go, but new trials and new mechanisms stay with us for the long haul. One of the more interesting new mechanisms is the FcRn drugs, and at ACR Convergence 2026 we got to see positive results from the Phase 3 ALKIVIA https://t.co/cCgItPQSPS
Dr. John Cush Tweet
@RheumNow
“Age old” biomarkers in ILD and pulmonary fibrosis At #ACR26, there was a poster on senescence being increased in SARD-ILD (systemic autoimmune rheumatic disease – interstitial lung disease) including fibrotic (progressive pulmonary fibrosis), showing epithelial remodeling from https://t.co/cNxgqJIH8T
Dr. John Cush Tweet
@RheumNow
AI vs Rheumatologist? The Better Answer May Be Both Can artificial intelligence answer patients’ rheumatology questions as well as a rheumatologist? Abstract 2965 at #ACR26 suggests the answer may be yes, but also highlights why physician oversight still matters. https://t.co/RNbCUFjMQo
Dr. John Cush Tweet
@RheumNow
Why Did the Last Drug Fail? When a patient fails a drug, we tend to consider what will be the next drug. Most of our clinics have patients on their second or third advanced therapy. Drug failure has become more common, not less. A question that we too rarely write in the notes https://t.co/r5mQjI79iQ
Dr. John Cush Tweet
@RheumNow
Looking for RA-ILD: 9 Clinical Clues from ANCHOR-RA Which of our RA patients will develop RA-ILD, and how can we better identify these patients? In abstract #2884 at #ACR26 , Dr. Jeffrey Sparks presented findings from ANCHOR-RA trial, a large prospective cross-sectional study https://t.co/P96KAcPmWt
Dr. John Cush Tweet
@RheumNow
Making the Case for Early Biologics in Lupus A new diagnosis of SLE can be overwhelming for patients. The decision to initiate biologic versus non-biologic therapy early in the disease course may have far-reaching implications for disease control, glucocorticoid exposure, and https://t.co/CmTeHTwzZw
Dr. John Cush Tweet
@RheumNow
Pregnancy After CAR-T in Autoimmune Disease: 14 Pregnancies, No Flares The first multicenter series of pregnancies after CAR T-cell therapy for autoimmune disease reports 8 healthy births and no maternal flares. It is the first dataset of its kind, and the numbers are small. https://t.co/uqWz8GeAmX
Dr. John Cush Tweet
@RheumNow
Menopause and Rheumatoid Arthritis: Are we asking enough? A study from Mayo Clinic at ACR Convergence, abstract 1849 examines menopause symptom burden in women with and without RA. Using two research datasets, Kristen Young and colleagues conducted a cross-sectional analysis of https://t.co/V3VJXo3z5w
Dr. John Cush Tweet
@RheumNow
Beyond HLA-B27: Anti-14-3-3eta Autoantibodies as a Candidate Marker in axSpA 14-3-3 proteins are a conserved family of seven isoforms with diverse cellular functions, found predominantly intracellularly. The 14-3-3eta isoform has been studied as a proinflammatory mediator in RA https://t.co/yC4bhtnTCD
Dr. John Cush Tweet
@RheumNow
PMR: Spare The Steroids Please Steroids remain both the cornerstone and the Achilles' heel of PMR management. We have aspirations of briskly tapering our patients once they have had their honeymoon phase with prednisone. But when Ms. Jones calls you with a reported second PMR https://t.co/dbrdVZRuoN
Dr. John Cush Tweet
@RheumNow
All RA-ILD deserves a trial of immunomodulation The optimum treatment approach in RA-ILD remains an area mired in controversy. This is evident from the contrasting views taken by the 2 recent expert guidelines from ACR and EULAR, which advocate for very different treatment https://t.co/vxr8NDruGI
Dr. John Cush Tweet
@RheumNow
New Treatment for Fibromyalgia? Will It Help or Harm? For years, the pharmacologic treatment landscape for fibromyalgia has remained relatively unchanged, with limited therapeutic options despite a substantial disease burden. This condition is characterized by chronic https://t.co/nn9wu7xibY
Dr. John Cush Tweet
@RheumNow
Biologic Dosing and Obesity A 46-year-old with pSa and a BMI of 38 still has active disease on adalimumab (Humira) 40 mg every other week. What do you do? Stephen Balevic, MD, PhD, discusses this question in "Prescribing the Right Dose: How Obesity Alters Drug https://t.co/0SGQGs32U2
Dr. John Cush Tweet
@RheumNow
One Diagnosis, Different Diseases: Is TLR7/8 Inhibition the Future of Lupus Treatment? We call it systemic lupus erythematosus (SLE), but are we really treating one disease? Increasingly, I wonder whether grouping biologically distinct patients under one diagnosis is limiting https://t.co/30MGwIRUgO

Video

Podcasts

  • Why I Go to ACR Convergence Every Year (11.13.2026)
  • ACR 2026 Daily Podcasts - Day4b
  • ACR 2026 RheumNow Day 4 Recap
  • ACR 2026 Daily Podcasts - Day4a
Ask Cush Anything

Submit your Rheumatology question or case here

Therapeutic Updates

Individualized PsA Treatment With an IL-23i or a JAKi

Sponsored by AbbVie Medical Affairs + Health Impact
AbbVie November RX Update
In Part 2 of our PsA management series, Saakshi Khattri, MD, and Lindsay Tom, PA-C, discuss tailoring treatment for patients with multidomain PsA and how IL-23i and JAKi data guide their decisions
Read Post
×